Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Brazil / NCT07420816
Recruiting Phase 2

Efficacy and Safety of APSTZD in the Treatment of Insomnia Disorder

NCT07420816 · tracked via the Priya Life Science Brazil tracker
Sponsor
Apsen Farmaceutica S.A
Phase
Phase 2
Started
2026-08-05
Last updated
2026-08-21

Condition(s) studied

InsomniaInsomnia Chronic

Investigational drug(s) / intervention(s)

APSTZD 1APSTZD 2APSTZD 3APSTZD 4Stilnox CR®Placebo

APSTZD 1: APSTZD + placebo test 2 + placebo test 3 + placebo test 4 + comparator placebo 1

APSTZD 2: APSTZD + placebo test 1 + placebo test 3 + placebo test 4 + comparator placebo 1

APSTZD 3: APSTZD + placebo test 1 + placebo test 2 + placebo test 4 + comparator placebo 1

APSTZD 4: APSTZD + placebo test 1 + placebo test 2 + placebo test 3 + comparator placebo 1

Stilnox CR®: Stilnox CR® + placebo test 1 + placebo test 2 + placebo test 3 + placebo test 4

Placebo: placebo test 1 + placebo test 2 + placebo test 3 + placebo test 4 + comparator 1

Study summary

The purpose of this study is to evaluate the efficacy of APSTZD compared to one active drug and placebo in insomnia treatment.

Eligibility

Sex
ALL
Min age
18 Years
Max age
64 Years
Healthy volunteers
No
Inclusion Criteria: * Participants aged between 18 and 64 years; * Participants diagnosed with insomnia disorder according to the criteria defined by the DSM-V (1) and who report sleep maintenance disorder; * Participants who agree not to use alcoholic beverages during the entire treatment period (6 weeks). Exclusion Criteria: * Participants with known hypersensitivity to the active ingredients used during the trial or who have exhibited complex sleep behavior after using them; * Participants with a history of alcohol, substance, or illicit drug abuse disorder in the last 2 years; * Women who are pregnant or breastfeeding, as well as women who have a positive result on a pregnancy test (β-hCG) during the screening period of the trial; * Participants diagnosed with severe liver failure;

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
UNIFAG - Casa Nossa Senhora da PAZ -ASF Bragança Paulista São Paulo Recruiting

More Apsen Farmaceutica S.A. trials in Brazil

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07420816 on ClinicalTrials.gov ↗ ← All trials in Brazil